Persistently high levels of released IFN-γ (during the first 3 months) or QFT conversion (after 20–24 months) strongly indicate the development of active tuberculosis in patients undergoing long-term anti-TNFα therapy [30]. The gene discussed is IFNG; the disease is tuberculosis.